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ABSTRACT 
 
 
 
EXPRESSION & PURIFICATION OF RECOMBINANT PLASMODIUM FALCIPARUM 
ERYTHROCYTE-BINDING LIGANDS 
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at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2010 
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Plasmodium falciparum, the most virulent malarial parasite, is capable of invading all 
known human blood types. Erythrocyte invasion depends on specific parasite ligand and 
erythrocyte receptor interactions. These interactions are mediated by Region II of the P. 
falciparum erythrocyte binding ligands. Although invasion does not seem dependent upon a 
singular ligand, their individual contributions to the invasion process are yet to be explained. In 
this study, Region II of P. falciparum binding ligands BAEBL and JESEBL were transiently 
expressed as hexahistidyl recombinant proteins in COS-1 cells. Purification by column 
chromatography yielded 0.52 mg of BAEBL RII and 0.433 mg of JESEBL RII. The production 
and purification of these recombinant hexahistidyl proteins can allow for future binding affinity 
and kinetic analysis that may eventually define the contributive roles of each ligand during 
erythrocyte invasion. 
 
 
 
 
 
 
INTRODUCTION 
 
 
 
Malaria Disease 
Malaria is a tropical disease manifesting in a wide range of symptoms. The less severe 
form, or uncomplicated malaria, includes general malaise, headache, fever, and chills. 
Contrastingly, symptoms of severe malaria can be presented as convulsions, respiratory distress, 
severe anemia, coma, and ultimately death. The range of symptoms and the disease itself are 
caused by species of the protozoan parasite Plasmodium. Although, Plasmodium can cause 
malaria in many different species, such as birds, mice, lizards, and monkeys, there are only five 
species that infect humans. These species are P. knowlesi, P. ovale, P. malariae, P. vivax, and P. 
falciparum. The most common species are P. vivax and P. falciparum, and they affect over 2.4 
billion people each year, resulting in more than 800 thousand deaths annually (WHO 2009).  P. 
falciparum is the most virulent and is the main contributor of the ever increasing number of 
malaria fatalities (WHO 2009).  
Malaria Transmission  
Plasmodium causes malaria during the asexual stage of its life cycle. This stage is 
comprised of two additional cycles, the exo-erythrocytic and erythrocytic. The exo-erythrocytic 
cycle begins with the inoculation of sporozoites into the host by the female Anopheles mosquito 
during a blood meal. These sporozoites then travel to the liver where they will undergo multiple 
nuclear divisions. This asymptomatic phase ends with the rupture of the infected hepatocyte and 
the release of individual merozoites into the blood stream. The clinical manifestations of malaria 
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do not occur until the erythrocytic cycle begins, when merozoites are actively invading and 
destroying erythrocytes (Tuteja 2007, for review). 
Plasmodium Invasion 
Erythrocyte invasion can be divided into four main steps; attachment, reorientation, 
junction formation, and entry. The first two steps, attachment and reorientation, are reversible 
and involve a loose attachment of the merozoite to the erythrocyte followed by reorientation of 
the merozoite. This results in the adjacent positioning of the parasite’s apical end to the 
erythrocyte surface (Dvorak et al. 1975). Following these steps is the irreversible junction 
formation. It is characterized by the thickening of the two adjacent cell membranes (Aikawa et 
al. 1978). At this point, the parasite is committed to the invasion of the erythrocyte. The 
erythrocyte membrane will then invaginate; completely surrounding the merozoite, separating it 
from the host cytosol in a parasitophorous vacuole (Aikawa et al. 1978). From within this 
vacuole, the parasite will replicate and eventually rupture the erythrocyte. 
Duffy Binding Like-Erythrocyte Binding Protein family 
The details of Plasmodium erythrocyte invasion were first uncovered in studies with 
Plasmodium vivax and the simian parasite, Plasmodium knowlesi. It was seen that P. knowlesi 
could invade human erythrocytes that carried the surface protein known as the Duffy antigen 
(Miller et al. 1975). When in the presence of erythrocytes without the Duffy antigen (Duffy 
negative), P. knowlesi merozoites could attach and reorient themselves, but no junction 
formation would occur and thus no erythrocyte invasion (Miller et al. 1979). Similarly, P. vivax 
merozoites were unable to invade Duffy negative erythrocytes and individuals with the Duffy 
negative phenotype were resistant to P. vivax infection (Miller et al. 1976, Barnwell et al. 1989). 
The merozoite surface protein that bound to this receptor was named Plasmodium vivax Duffy 
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Binding Protein (PvDBP, Wertheimer et al. 1989). The process of characterizing this protein, 
and the DBP of P. knowlesi,  lead to the discovery of homologues in Plasmodium falciparum, as 
well as the establishment of the Duffy Binding Like-Erythrocyte Binding Protein family (DBL-
EBP family) (Fig. 1). Members of the DBL-EBP family are primarily characterized by a 
cysteine-rich amino terminal region, the DBL domain, which is able to bind to erythrocytes 
(Adams et al. 1992). There is an additional cysteine-rich region at the carboxy-terminal which is 
adjacent to a putative transmembrane domain and short cytoplasmic tail (Adams et al. 1992).  
 Plasmodium falciparum Erythrocyte Binding Ligands 
For P. vivax, PvDBP mediates junction formation and invasion into the human 
erythrocyte by interaction with the Duffy antigen (Miller et al. 1979). There is only one 
erythrocyte receptor that is recognized, only one blood type that is susceptible to invasion. 
Therefore, P. vivax has only one known invasion pathway. This is not the case for Plasmodium 
falciparum. There is no known blood type that is resistant to Plasmodium falciparum invasion 
and multiple parasite DBL-EBPs unique to P. falciparum play a role in this promiscuity (Donlan 
et al. 1994). The DBL-EBPs of P. falciparum are named Erythrocyte Binding Antigen-175 
(EBA-175), Erythrocyte Binding Antigen-140 (EBA-140/BAEBL), Erythrocyte Binding 
Antigen-181 (EBA-181/JESEBL), Erythrocyte Binding Ligand-1 (EBL-1), and the untranslated 
pseudogene EBA-165/PEBL (Camus et al. 1985, Adams et al. 2001, Thompson et al. 2001, 
Gilberger et al. 2003, Peterson and Wellems 2000, Triglia et al. 2001). 
Each of these proteins contains the cysteine-rich DBL domain, but unlike the 
Plasmodium vivax Duffy Binding Protein, the DBL domain is duplicated (Adams et al. 1992).  
The duplicated DBL’s are termed F1 and F2, and are collectively known as Region II (Chitnis 
and Miller 1994) (Fig. 1). Region II has been shown to be necessary and sufficient for 
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recognition of and binding to the surface of human erythrocytes (Sim et al. 1994). Moreover, 
polymorphisms in Region II across different strains of P. falciparum DBL-EBP’s have altered 
erythrocyte binding specificity and affinity (Mayer et al. 2002 & 2004, Maier et al. 2010).  
While the receptors for EBA-175, BAEBL (strain Dd2/NM), and EBL-1 have been 
identified as Glycophorin A, Glycophorin C, and Glycophorin B respectively, the erythrocyte 
receptor for JESEBL is still unknown (Sim et al. 1994, Mayer et al. 2001, Mayer et al. 2002, 
Lobo et al. 2003, Maier et al. 2003, and Mayer et al. 2009). Also unknown, is how these proteins 
function with respect to one another on the surface of the merozoite. It has been shown that even 
with single gene disruptions of EBA-175, BAEBL, and JESEBL, P. falciparum is still able to 
invade erythrocytes, possibly suggesting redundancy among the roles of these proteins (Kaneko 
et al. 2000, Reed et al. 2000, Maier et al. 2002, Duraisingh et al. 2003, and Gilberger et al. 
2003).  
Thesis Objectives 
In an attempt to investigate the contributions of the Plasmodium falciparum Erythrocyte 
Binding Proteins in erythrocyte recognition and binding, the goal of this study was to express 
Region II (RII) from EBA-175, BAEBL, and JESEBL and purify them for future kinetic and 
binding affinity studies. Because the purpose of purifying these proteins was to assess their 
functional binding properties, it was imperative to utilize cells that would carry out the proper 
post-translational modifications. A bacterial system would not be sufficient, in that, Plasmodium 
is a eukaryotic organism and protein processing differs in prokaryotes which would result in the 
production of nonfunctional recombinant proteins (Kingston and Brent 2007). Region II of P. 
falciparum DBL-EBPs has been successfully expressed in mammalian cells, maintaining their 
ability to recognize the appropriate receptor on the surface of human erythrocytes (Mayer et al. 
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2002, 2004 & 2009). Therefore, mammalian cell lines were chosen for this study as opposed to 
other systems; such as yeast, which has been shown to over glycosylate RII of the P. falciparum 
DBL-EBPs (Tolia et al. 2005). A secondary objective was to assess two previously-established, 
stably-transfected cell lines expressing EBA-175 RII and BAEBL RII. Purification of these 
recombinant proteins, from respective transiently or stably expressing cell lines, will allow for 
future analysis of the individual and contributive roles of these proteins during erythrocyte 
recognition and attachment.  
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METHODS & MATERIALS 
 
 
 
Cloning of JESEBL RII 
 
Both EBA-175 RII and BAEBL RII had been successfully cloned for the creation of 
stably expressing cell lines; however, JESEBL had not (D. Gertner Master Thesis). In order to 
establish a cell line for JESEBL, the jesebl RII gene was cloned. Using 100 nanograms (ng) of 
the genomic DNA from P. falciparum strain Dd2/NM, as a template, RII of jesebl was amplified 
by polymerase chain reaction (PCR). The oligonucleotide primers, used at a concentration of 20 
picomoles per microliter (pmol/μl), to amplify jesebl RII were as follows: 5’-ATC GGT ACC 
TAT TTG AAT AGA AAT AGT TTT G-3’ (forward) and 5’-AAT GGA TCC TGA GTC TAT 
AGA TAA CAT TTC TTT G-3 (reverse).  These primers were designed to incorporate the 
restriction endonuclease sites for KpnI and BamHI, respectively. The PCR parameters were as 
follows; 94º C for 1 min, 30 cycles of 30 sec at 92º C, 50 sec at 38º C, 3 min at 68º C, followed 
by 5 min at 68º C. These PCR conditions resulted in the expected product of about 1.9 kilobases 
(kb) (Fig. 2). 
PCR products were purified with the QIAquick PCR Purification Kit according to Qiagen 
protocol (Qiagen, Valencia, CA). The purified PCR products and the plasmid vector (Fig. 3) 
were then digested with the FastDigest restriction endonucleases BamHI and KpnI, according to 
the manufacturer’s protocol (Fermentas, Glen Burnie, MD). To prevent the rejoining of the 
digested plasmid vector, the 5-prime phosphate groups were removed using calf intestinal 
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phosphatase (CIP) (New England Biolabs, Ipswich, MA). Ligation reactions were carried out at 
16º C with T4 DNA Ligase (New England Biolabs, Ipswich, MA) overnight. 
The plasmid vector used during the cloning process was pcDNA.3.1/myc-His B (Fig. 3) 
(Invitrogen, Carlsbad, CA) and it has many features that aided in the cloning process, as well as 
expression of the recombinant JESEBL RII in mammalian cells. For cloning utilizing E. coli, the 
T7 promoter and pUC origin of replication allowed for in vitro transcription and increased 
plasmid replication, respectively. Other advantages were the multiple cloning sites for a variety 
of in-frame insertions sites and the β-lactamase gene, conferring resistance to ampicillin during 
selection for positive clones. Lastly, to facilitate sequencing, the T7 priming and BGH reverse 
priming sites were present in the vector.  
Transformation into XL10-Gold Ultracompetent E. coli (Stratagene, La Jolla, CA) was 
performed according to the Stratagene protocol and clones were selected on LB agar plates, 
supplemented with ampicillin at a concentration of 50 milligrams per milliliter (mg/ml). Ten 
colonies chosen at random and expanded into 5 ml LB broth cultures, also supplemented with 50 
mg/ml ampicillin. Plasmid DNA was isolated from these cultures using the QIAprep Spin 
Miniprep Kit (Qiagen, Valencia, CA), following the manufacturer’s protocol. To assess if the 
isolated plasmid DNA contained the jesebl RII insert, the DNA was digested with BamHI and 
KpnI, as described above, and the products were analyzed by agarose gel electrophoresis (Fig. 5). 
Positive clones for JESEBL RII were sequenced with two external primers annealing to the T7 
and BGH priming sites of the plasmid vector, as well as six internal primers (Fig. 6) derived 
from the expected sequence (Nucleic Acids Research Facilities, VCU, Richmond, VA). The 
clone with the highest similarity to the expected gene sequence for JESEBL RII (genebank 
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#AY495681) was selected for transfection (Fig. 7). The translated gene sequence from the 
positive clone was also compared to the expected protein sequence (Fig. 8).  
Transfection of EBA-175 RII, BAEBL RII, and JESEBL RII into COS-1 Cells 
For expression in mammalian cells, the pcDNA.3.1/myc-His B vector contains the human 
cytomegalovirus (CMV) immediate-early promoter/enhancer sequences for elevated 
recombinant protein expression and the SV40 polyadenylation signal for proper transcription 
termination and mRNA polyadenylation. The geneticin (G418) resistance gene allowed for 
selection of transfected cells and the simian vacuolating virus 40 (SV40) early promoter and 
origin to drive expression of said gene. The remaining two features of this plasmid vector, the 
carboxyterminal hexahistidyl and myc epitopes, permitted purification and identification during 
assays. The hexahistidyl epitope allowed the recombinant protein to be separated from a cell 
lysate by binding to metal-chelating resin during column chromatography purification.  The myc 
epitope was utilized for some preliminary immunoblotting assays, with the anti-myc antibody for 
detection. 
African Green Spider Monkey Kidney Cells (COS-1) were chosen for transient 
transfection of the JESEBL RII, EBA-175 RII and BAEBL RII plasmid DNA. This cell line was 
chosen for its ability to accept exogenous DNA with the SV40 origin and express that DNA at 
very high levels within a seven day period (Aruffo 2003). The method for transfection was 
cationic lipid-mediated endocytosis, using the Lipofectamine 2000 Reagent (Invitrogen, 
Carlsbad, CA) and all transfections were done in duplicate. Prior to transfection, 1 x 106 cells 
were cultured in each well of a six-well plate with 2 ml of Dulbecco’s Modified Eagle's Medium 
(DMEM) (High- HyClone, Carlsbad, CA) and incubated at 37º C with 10% CO2 for 24 hours. 
The DMEM was supplemented with 10% fetal bovine serum (FBS) (HyClone, Carlsbad, CA), 
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Sodium Bicarbonate (3.7g/L), and 1% Penicillin/Streptomycin (Pen/Strep). A mock transfection, 
without DNA, was also performed as a control. Transfection reactions were incubated in the 
supplemented DMEM, without antibiotics, in six-well plates at 37º C with 10% CO2.  
Twenty-four hours post-transfection, the cells were washed twice with 2 ml 1X 
Phosphate Buffer Saline (PBS) and incubated with 500 microliters (µl) of Trypsin-EDTA for 3 
minutes at 37º C. Cells were harvested with 2 ml of the supplemented DMEM with Pen/Strep 
and centrifugated at 652 x g. The harvested cells were then resuspended in 25 ml of the 
supplemented DMEM with Pen/Strep and added to a 75 cm3 rectangular canted neck flask 
(Corning, Lowell, MA). Flasks were incubated at 37º C with 10% CO2.  At seventy-two hours 
post transfection, the cells from one flask of each transfection (three recombinant cultures and 
one mock transfection culture) were harvested for protein analysis and the other cells were used 
for 6X-His protein purification with column chromatography using a nickel resin column. 
Transfected CHO-K1 Cell Culture  
Previously established CHO-K1 cells transfected with EBA-175 RII and BAEBL RII (D. 
Gertner Master’s Degree Thesis) were cultured in 150 cm3 rectangular canted neck flasks 
(Corning, Lowell MA) with 50 ml of RPMI-1640 (HyClone, Carlsbad, CA) selection media. 
This media was supplemented with 10% FBS, 1% L-Glutamine, 1% Pen/Strep, and 20 mg/ml 
Geneticin (Invitrogen, Carlsbad, CA).  Every 48 hours, the cells were washed twice with 10 ml 
of PBS (pH 7.4). Cells were incubated with 5 ml Trypsin-EDTA and harvested by centrifugation 
at 652 x g. Harvested cells were resuspended in RPMI-1640 selection media and one tenth of the 
resuspension was transferred to a new flask with fresh media. Cells were cultured at 37º C with 
10% CO2. 
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Immunoflorescence Assays 
Recombinant protein expression of CHOK-K1 cell lines was assessed by 
Immunoflorescence assay (IFA). Round, glass cover slips were incubated with poly-L-lysine in 
six-well plates at room temperature for 15 minutes. After incubation, poly-L-lysine was aspirated 
from the wells and a suspension of 1 x 106 cells was added to it. Cover slips were incubated with 
cells for 24 hours at 37º C to allow for adherence. The cover slips were then washed three times 
with PBS (pH 7.4) and the cells were fixed with 25 μl 1% formaldehyde in PBS (pH 7.4) for 5 
minutes at room temperature. Cover slips were washed again three times with PBS (pH 7.4) and 
incubated for 30 minutes with 30 μl of blocking buffer; 0.1% Triton X-100 (Bio-Rad, Hercules, 
CA) and 2.5 mg/ml Normal Goat Serum (NGS) (Jackson Immuno Research, West Grove, PA) in 
PBS (pH 7.4). 
Antisera against the specific P. falciparum EBP Region II was diluted 1:100 in blocking 
buffer and cover slips were incubated with 30 μl of this dilution. Following incubation, cover 
slips were washed three times in PBS (pH 7.4) for five minutes. Cover slips were then incubated 
with 25 μl of a 1:200 dilution of Alexa Fluor 488 fluorescent dye-conjugated antibodies 
(Molecular Probes, Carlsbad, CA) against the appropriate primary antisera (anti-rabbit for EBA-
175 and anti-rat for BAEBL). As a control, the cells were incubated with the secondary antibody 
alone. Following washes, slides were mounted with fluorescent mounting media (KPL, 
Gaithersburg, MD) and sealed with clear nail enamel for viewing on the BX41 System 
Microscope (Olympus, Center Valley, PA). One thousand cells per slide were counted and the 
percentages of cells fluorescing were recorded.  
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Genomic DNA Extraction & PCR Analysis of Transfected Cell Lines 
For analysis of the incorporation of the transfected DNA into the genome of the stably 
transfected cell lines, genomic DNA was isolated. Cells from flask cultures were harvested, as 
described above, and the cell pellets were resuspended in 2 ml of ice cold PBS (pH 7.4). The cell 
suspension was then centrifugated at 500 x g for 5 minutes. The supernatant was discarded, the 
cells were resuspended, and the suspension was centrifugated again. The supernatant was again 
discarded and the cell pellet was then resuspended in 300 μl of digestion buffer (Strauss 1998). 
This resuspension was then incubated at 50º C for 16 hours with rotation. DNA was extracted 
from this cell lysate with 100 μl of phenol, 100 μl of chloroform, 100 μl of isoamyl alcohol and 
centrifugation at 1700 x g for 10 minutes. The aqueous top layer was collected and 75-100 μl of 
7.5M ammonium acetate (1/2 volume of the aqueous top layer) were added to it. DNA was 
precipitated with 300-400 μl of 100% ethanol (2 times the volume of the aqueous top layer). 
DNA was pelleted though centrifugation at 1700 x g for 4 minutes, 2570 x g for 2 minutes, and 
16,060 x g for 1 minute. DNA pellets were washed with 100 μl of 70% ethanol and air dried. 
DNA pellets were resuspended in 500 μl of Tris-EDTA buffer (TE) for a final concentration of 
approximately 1 mg/ml. 
For detection of the EBA-175 RII and BAEBL RII genes, PCR amplification was 
performed with the original primers used for cloning. Purified DNA solutions were diluted to a 
concentration of 100 ng/μl for use as the PCR templates and all primers were at a concentration 
of 20 pmol/μl. For EBA-175 RII forward (5’-ATC GGT ACC AAT AAA TAT GTT CCT ATT 
AAC-3’) and reverse (5’-ATC GGA TCC ACA CAT CGT ACA TTT ATT TTT ATA AT-3’) 
primers were used, and for BAEBL RII forward (5’-ATC GGT ACC CAA TAT ACG TTT ATA 
CAG AAA CGT AC-3’) and reverse (5’-ATC GGA TCC TAT ATC GTG TTT TGT TTT AGG 
11 
 
ATA TTT A-3’) primers were used. As a control, a 435 bp fragment of the constitutively active 
Chinese Hamster glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene was amplified 
with the following forward (5’-GGT CGG CGT GAA CGG ATT TGG CCG-3’) and reverse 
primers (5’-CGC ATT GCT GAC AAT CTT GAG GGA G-3’) (Holdsworth et al. 2005). The 
PCR parameters were as follows; 94º C for 1 min, 30 cycles of 30 sec at 92º C, 50 sec at the 
annealing temperature, 3 min at 68º C, followed by 5 min at 68º C. The annealing temperatures 
were 52º C, 58º C, and 62º C for the EBA-175 RII, BAEBL RII, and GAPDH primers, 
respectively. 
RNA Extraction from Transfected Cell Lines & Reverse-Transcriptase PCR Analysis 
For analysis of transcription from the transfected DNA of stably transfected cell lines, 
total RNA was isolated. Cells from flask cultures were harvested, as before, and the cell pellets 
were resuspended in 2 ml of TRIzol reagent (Invitrogen, Carlsbad, CA). Cell suspensions were 
then centrifugated at 12,000 x g for 10 minutes at 4º C. The aqueous top layer was removed and 
incubated at room temperature for 5 minutes before adding 400 μl of chloroform and shaking 
vigorously. The sample was incubated at room temperature for another 3 minutes, then 
centrifugated at 12, 000 x g for 15 minutes at 4º C. The aqueous top layer of RNA was removed, 
added to 1 ml of isopropanol, and incubated for 10 minutes at room temperature. RNA samples 
were again centrifugated at 12,000 x g for 10 minutes, at 4º C. The supernatant was discarded 
and the RNA pellet was washed with 2 ml of 75% ethanol. Ethanol was removed after a 5 
minutes centrifugation at 7,500 x g and the pellet was air dried for 10 minutes. The RNA pellet 
was then dissolved in 200 μl RNase-free distilled water at 55º C for 10 minutes. All 
microcentrifuge tubes, pipettes, gloves, and work areas were treated with RNase Away 
(Invitrogen, Carlsbad, CA) prior to isolation. 
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Complementary DNA (cDNA) was synthesized from the purified total RNA samples. 
This was completed using the iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA). Reactions 
were prepared as indicated in the product protocol, using 1 μg of purified total RNA as a 
template. In addition to the cDNA synthesis reactions with the RNA, reactions without iScript 
Reverse Transcriptase were performed as a control. Both sets of reverse transcriptase PCR (RT-
PCR) products were utilized as templates in an additional PCR amplification of the EBA-175 
RII, BAEBL RII, and GAPDH genes using the same primers and parameters as stated above 
with the isolated genomic DNA. 
ProBond Purification of Hexahistidyl Recombinant Proteins 
Recombinant P. falciparum EBPs, from both transiently and stably transfected cell lines, 
were purified using the ProBond Purification System (Invitrogen, Carlsbad, CA) utilizing the 
hexahistidyl epitope that was incorporated into the protein through the pcDNA.3.1/myc-His B 
plasmid vector. Cell lysates were prepared by first harvesting cell, as stated above. Cell pellets 
were resuspended in 8 ml of native binding buffer (250mM monobasic sodium phosphate, pH 
8.0 and 2.5M sodium chloride). Cells were then lysed by two cycles of freezing in a dry-
ice/ethanol bath and thawing in a 42º C water bath. DNA in these cell lysates were then sheared 
by passing the lysate through a 21 gauge needle, four times. Lysates were then centrifugated for 
15 minutes at 3000 x g to pellet the cellular debris. The supernatant was then collected for 
column chromatography with a nickel- iminodiacetic acid (IDA) resin column according to the 
Invitrogen protocol for native conditions. Purified eluates were colleted form the columns in 1 
ml aliquots. 
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Immunoblot Analysis 
All eluates and washes were analyzed through immunoblotting with antisera for the 
specific P. falciparum EBPs. Protein samples were prepared in Laemmli sample buffer with 5% 
β-mercaptoethanol (Bio-Rad, Hercules, CA). Protein samples were denatured by heating at 90º C 
for 5 minutes before loading into a discontinuous 10% polyacrylamide gel. Protein samples were 
separated on the polyacrylamide gels by electrophoresis with a constant current of 30 mAmp for 
1 hour and 15 minutes in 1X NuPAGE® MOPS SDS running buffer (Invitrogen, Carlsbad, CA).  
Proteins on the polyacrylamide gels were then transferred to a polyvinylidene fluoride 
membrane (PVDF) (Pierce, Rockford, IL) using electrophoresis with constant voltage at 100 
volts (V) for 2 hours, in transfer buffer (Gallagher et al. 2008). PVDF-bound proteins were then 
incubated with blocking buffer; 10% nonfat milk (Bio-Rad, Hercules, CA) in PBS with 1% 
Tween 20 (Bio-Rad, Hercules, CA) for 1 hour to block the membrane from nonspecific binding. 
Primary antisera for each P. falciparum EBP was diluted 1:1000 in blocking buffer and 
incubated with the membrane overnight at 4º C. Following incubation with primary antisera, the 
membranes were washed 3 times with PBS with 1% Tween 20 for 5 minutes each time. The 
membranes were then incubated with horseradish peroxidase (HRP) conjugated secondary 
antisera in a 1:5000 dilution in blocking buffer for 1 hour at room temperature, followed by 
another series of three washes. All incubations were carried out on a rotating platform. Presence 
of recombinant proteins was detected with the Amersham Enhanced Chemiluminescence (ECL) 
(General Electrics, Piscataway, NJ ) followed by autoradiography.  
Protein Quantification 
Purified hexahistidyl recombinant P. falciparum erythrocyte binding proteins were 
quantified using a modified Lowry protein assay, the DC Protein Assay (Bio-Rad, Hercules, 
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CA). The colormetric assays were performed according to the manufacturer’s protocol. 
Triplicate absorbencies of five known concentrations of Bovine Serum Albumin (BSA); 0.2 
mg/ml, 0.525 mg/ml, 0.85 mg/ml, 1.175 mg/ml, and 1.5 mg/ml were taken at 750 nanometers 
(nm) using the Cary 50 UV-Visual Spectrophotometer (Varian Inc., Palo Alto, CA). A standard 
linear curve was produced from the average absorbencies using the Cary WinUV Concentration 
Application (Varian Inc., Palo Alto, CA). Triplicate absorbencies of recombinant hexahistidyl 
JESEBL RII and BAEBL RII from the COS-1 cells were taken, along with the BAEBL RII from 
the CHO-K1 cell line. Average absorbencies of the three samples were plotted along the standard 
curve for calculation of the protein concentration.  
Electrophoresis of Protein Eluates 
Purity of the eluted hexahistidyl proteins were verified by subjecting 30-40 µl, 14-15 
micrograms (µg), of the chromatography eluates to sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE), as described above, followed by staining with SYPRO Ruby 
Protein Gel Stain (Sigma-Aldrich, St. Louis, MO). Staining was performed according to 
manufacturer’s protocol.  
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RESULTS 
 
 
 
The Cloning of jesebl RII 
Polymerase chain reaction conditions with primers for the JESEBL RII gene yielded a 
DNA product of the expected size, 1.9 kb (Fig. 2). Agarose gel electrophoresis of restriction 
endonuclease reaction products confirmed the 5.5 kb size of the linearized plasmid vector 
pcDNA.3.1/myc-His B (Fig. 4). Following transformation of the ligated plasmid into XL-10 gold 
competent E. coli, ten positive clones were selected at random and again digested with KpnI and 
BamHI restriction endonucleases for detection of the inserted jesebl RII. Of the ten clones, two 
did not contain the jesebl RII insert (Fig. 5). The other eight were sequenced and aligned to the 
expected DNA sequence of jesebl RII (Accession# AY495681) (Fig. 7). Of the eight clones, 
clone 10 showed homology to the expected sequence with one singular base-pair change of a 
thymine (T) to cytosine (C) leading to a silent mutation (Fig. 8).  
Recombinant Protein Expression Analysis of Transfected COS-1 Cell Lines  
Purification of hexahistidyl containing proteins by nickel-IDA column chromatography 
was necessary for detection of recombinant JESEBL RII and BAEBL RII (Fig. 9). However, 
recombinant EBA-175 RII was not detected in purified hexahistidyl eluates. Therefore, by these 
methods, only JESEBL RII and BAEABL RII were successfully expressed as hexahistidyl 
recombinant proteins and purified from COS-1 cells. Furthermore, the purified hexahistidyl 
recombinant proteins electrophoresed at a higher molecular weight than the expected 75 
kilodaltons (kDa) for BAEBL RII and 77 kDa for JESEBL RII. Instead, both proteins were 
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closer to 100 kDa (Fig. 9b and c). There are at least five putative glycosylation sites within 
region two of EBA-175 and it is possible that the recombinant proteins, JESEBL RII and 
BAEBL RII, have been glycosylated at similar sites within region II (Tolia, et al. 2005). Two of 
the five could have allowed for N-glycosylation and three would have allowed for O-
glycosylation. The combination of these possible modifications could have resulted in the nearly 
25 kDa increase in the expected size of the recombinant proteins. Generally speaking, 
Plasmodium falciparum does not exhibit native N- or O-glycosylation, having a very a low 
abundance of proteins with these carbohydrate modifications. The carbohydrate linker region of 
Glycosylphosphatidylinositol (GPI) anchors comprise the majority of the glycosylation seen in 
Plasmodium proteins (Gowda and Davidson 1999, for review). However, since recombinant P. 
falciparum EBPs have previously been expressed in mammalian cells and still retained the 
ability to recognize and bind to the appropriate erythrocyte receptor, this possible glycosylation 
may not interfere with later binding assays but will be taken into consideration in the future 
(Mayer et al. 2002, 2004 & 2009).  
Establishment of Stable Cell Lines 
BAEBL RII and EBA-175 RII transfected CHO-K1 stable cell lines were received at 
50% expression as determined by IFA and appeared to increase to 100% within 4-5 weeks (Fig. 
10 & Fig. 11). Incorporation of the transfected DNA into the genome of the stably transfected 
cell lines was confirmed by the PCR amplification of baebl RII and eba-175 RII from isolated 
genomic DNA (Fig. 12 and Fig. 13). DNA products of nearly 2kb were produced with the baebl 
RII and eba-175 RII primer sets from genomic DNA, isolated from the respective cell lines. No 
band was detected from the untransfected cell lines using the same primer sets (Fig. 12 and Fig. 
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13). Therefore, the transfected DNA was confirmed to have been incorporated into the genome 
of the CHO-K1 cell lines after weeks under selective pressure with geneticin.  
Further analysis of the stable cell lines included detection of RNA produced from the 
incorporated baebl RII and eba-175 RII. RNA was isolated from these cell lines and subjected 
RT-PCR, followed by traditional PCR with the appropriate primer sets, as stated before. The 
agarose gel electrophoresis confirmed amplification of baebl RII from the cDNA but not eba-175 
RII (Fig. 14 and Fig. 15). Therefore, only the BAEBL RII transfected CHO-K1 stable cell line 
exhibited incorporation of the plasmid DNA into the genome and transcription of this DNA. It is 
possible that the EBA-175 RII gene was incorporated in such a location that allowed for the 
adjacent geneticin resistance gene to be expressed for survival under selective pressure, but 
somehow silenced eba-175 RII. Since CHO-K1 cells have the ability to amplify genes that are 
needed on a constitutive basis, it is possible that the geneticin resistance gene was amplified 
allowing continued survival in the geneticin pressure without the expression of the EBA-175 RII 
gene (Kingston et al. 1993). The results of the EBA-175 transfected CHO-K1 IFA contradict 
these RT-PCR results. The antisera for EBA-175 RII should not have bound to the cells, 
resulting in fluorescence by the bound fluorophore-conjugated secondary antibody, if in fact; the 
protein was not present in the cells. It is curious as to the specificity of the antisera for region II 
of EBA-175 during IFAs, in that the same antisera failed to detect EBA-175 RII during 
immunoblot analysis of EBA-175 RII transfected CHO-K1 cells. Perhaps the IFA protocol is not 
optimized for the EBA-175 RII antisera. 
With the incorporation of babel RII into the genome of the CHO-K1 cell line confirmed 
and transcription of the gene detected through RT-PCR, analysis of protein production was 
completed by immunoblotting. After purification by nickel-IDA column chromatography, the 
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hexahistidyl recombinant BAEBL RII was detected. As was seen with the COS-1 cell lines, the 
resulting protein band resolved closer to 100 kDa (Fig. 16).  
Quantification of Hexahistidyl Recombinant Proteins from Transfected COS-1 and CHO-
K1 Cell Lines  
After completion of the DC protein assay, absorbencies at 750 nm were taken for the five 
BSA concentrations; 0.2 mg/ml, 0.525 mg/ml, 0.85 mg/ml, 1.175 mg/ml, and 1.5 mg/ml. A 
graphical representation of the linear relationship between concentration and absorbance was 
plotted (Fig. 17) and the equation for this relationship was calculated to be; absorbance= 0.17353 
x concentration + 0.05848, with a r2 = 0.99795. According to this standard curve equation, three 
75 cm3 flasks of COS-1 cells expressing hexahistidyl recombinant P. falciparum JESEBL RII 
and BAEBL RII yields 0.433 and 0.520 mg of purified protein, respectively. For the BAEBL RII 
stably transfected CHO-K1 cell culture, one 150 cm3 flask yielded 0.366 mg of the hexahistidyl 
recombinant protein.  
Electrophoresis Analysis of the Purified Recombinant JESEBL RII and BAEBL RII  
To determine the purity of the eluates produced from transfected cell lines, samples were 
subjected to SDS-PAGE followed by staining with SYPRO Ruby (Sigma-Aldrich, St. Louis, 
MO). A single band of 75-100 kDa, as expected, was detected from the eluate of COS-1 cells 
transfected with BAEBL RII (Fig. 18). The absence of other bands in this eluate suggested no 
contamination with endogenous COS-1 cell proteins. On the contrary, the BAEBL RII 
transfected CHO-K1 eluate showed the presence of many different bands ranging in size from 
40-250 kDa (Fig. 18). These bands included the recombinant BAEBL RII protein between 75-
100 kDa, as expected. The presence of these additional proteins suggests that there were other 
hexahistidyl proteins within the CHO-K1 cell lysate that were co-purified with the recombinant 
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proteins. Therefore, the recombinant BAEBL RII represents only a fraction of the total 
calculated protein yield of 0.366 mg, and so this system would not be ideal for downstream 
binding affinity and kinetic analysis requiring a highly homogenous sample of a singular protein.  
There were no visible bands detected in the JESEBL RII transfected COS-1 cell eluate 
(Fig. 18). This was unexpected, as the immunoblots detected the recombinant protein resolving 
at the expected size between 75-100 kDa. It is possible that because the electrophoresis and 
staining analysis was performed at a much later date that the initial immunoblot assays, the 
recombinant protein was degraded. The initial storage of the eluates did not include glycerol or 
protease inhibitors, as it was to be a temporary storage for rapid immunoblot analysis. 
Additionally, the introduction of these additives may have interfered with downstream 
applications. Therefore, to avoid this problem in the future, the protein samples must be analyzed 
by electrophoresis and staining prior to immunoblot analysis and subsequent binding affinity and 
kinetic analysis should be performed immediately.  
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DISCUSSION 
 
 
 
Malaria is an endemic disease affecting over 2.4 billion people annually in Africa, Mid-
East Asia, the South Pacific Islands, Central and South America. P. falciparum is responsible for 
the majority of the over 800, 000 deaths resulting from severe forms of the malarial disease. Not 
only does this parasite have the ability to infect erythrocytes from all known blood types, many 
strains are increasingly becoming resistant to currently used anti-malarial drugs (Sibley and 
Ringwald 2006, for review). An effective vaccine that protects against P. falciparum malaria has 
yet to be developed. It has been shown that antibodies against EBA-175 can reduce invasion, but 
this is just one of the many invasion pathways utilized by P. falciparum and these competitive 
antibodies do not completely eliminate invasion (Sim et al. 1990 and Narum et al. 2000).  
The ability of P. falciparum to recognize and bind to the appropriate erythrocyte receptor 
during junction formation is critical for invasion. This specific interaction is mediated by Region 
II of the P. falciparum Erythrocyte Binding Proteins (Sim et al. 1994). As stated before, it is 
thought that invasion does not depend on any one binding ligand; as invasion is still possible 
even after single gene disruptions of EBA-175, JESEBL, and BAEBL, or in naturally occurring 
isolates lacking BAEBL (Guar et al. 2004, for review). However, the contribution of each 
individual ligand to the invasion process has yet to be explained. Glycophorins A, B, and C have 
been identified as receptors for ligands EBA-175, EBL-1, and BAEBL, respectively (Sim et al. 
1994, Mayer et al. 2001, Mayer et al. 2002, Lobo et al. 2003, Maier et al. 2003, and Mayer et al. 
2009). Although the binding profile for JESEBL has been described, the receptor for the ligand 
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is still unknown (Gilberger et al. 2003). In addition to identifying the receptor for JESEBL, 
identifying the binding affinities of these ligands for their respective receptors and understanding 
the kinetics of these interactions could help to further elucidate the invasion process as a whole. 
Competitive binding studies can give insight into these interactions and possibly aid in the 
development of alternative treatments for P. falciparum malaria or additive treatments to current 
anti-malarial medications. Such treatments could include a cocktail of synthetically derived 
competitive receptors for each of the P. falciparum binding ligands. If the binding affinities of 
the erythrocyte receptors and parasite ligands were defined, competitive receptors could be 
designed to bind with stronger affinities for the ligand than the respective erythrocyte receptors.  
Region II of P. falciparum Erythrocyte Binding Proteins BAEBL and JESEBL were 
produced as hexahistidyl recombinant proteins in COS-1 mammalian cells. From three medium 
(75 cm3) flasks of these cultures, respectively, 0.52 mg and 0.433 mg of these recombinant 
proteins were purified. Additionally, 0.36 mg of recombinant hexahistidyl BAEBL RII was 
purified from a previously established stable CHO-K1 cell line. However, there appeared to be 
additional proteins in the eluate from this stable cell line; multiple bands were detected in the 
SYPRO-stained polyacrylamide gels of the eluate from the CHO-K1 cells expressing BAEBL 
RII. It is possible that these proteins are interacting with the recombinant BAEBL RII. However, 
this is doubtful since no such interacting proteins were observed in the COS-1 cell lines. Perhaps 
there are post-translational modifications occurring in the CHO-K1 cell line, but not the COS-1 
cell, allowing for interaction of BAEBL RII with other proteins or with itself. Further research 
will need to be performed to explore these possibilities.  
Another explanation for the additional bands in the CHO-K1 eluate could be that 
endogenous CHO-K1 hexahisitdyl proteins were co-purified with the recombinant hexahistidyl 
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BABEL RII. Invitrogen (manufacturer of the ProBond Purification System) suggests rectifying 
co-purification by a more stringent washing of the resin with a lower pH buffer before eluting the 
bound proteins or even a second round of chromatography with a new column. However, since 
both of these methods could result in the loss of protein product and ultimately require more 
reagents, the recombinant BAEBL RII produced in the COS-1 cells could be used in place of the 
recombinant BAEBL RII produced in the CHO-K1 cells. Therefore, the COS-1 cell line would 
be the preferred expression system for the P. falciparum erythrocyte binding ligands, as the 
purified recombinant protein samples from these cells were shown to be free of contaminants.  
With the production and purification of 400-500 µg of the COS-1 produced recombinant 
hexahistidyl Plasmodium falciparum erythrocyte binding proteins, binding affinity and kinetic 
analysis can be performed using the BIACORE system (General Electrics, Piscataway, NJ), 
which requires as little as 0.03 µg to 30 µg of 99% purified protein samples for testing. The 
BIACORE system can allow for the recombinant EBPs to be attached by the hexahistidyl epitope 
to a gold chip with RII exposed to a flow chamber. Using a surface plasmon resonance derived 
sensogram, the binding kinetics of the recombinant proteins can be described over time as 
erythrocytes, or purified receptors, in the flow chamber media are bound and released from the 
recombinant proteins. The information gathered from the resonance signal includes association 
rate, equilibrium, and dissociation rate once the bound receptors are washed away (Katsamba et 
al. 2002). With the BIOCORE technology, the binding affinity of multiple P. falciparum 
hexahistidyl recombinant EBPs can be tested simultaneously. Candidates for receptors of 
JESEBL can also be examined. 
Binding affinity and kinetic analysis of the Plasmodium falciparum erythrocyte binding 
proteins could ultimately help to elucidate the contributive roles of each ligand in the recognition 
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of, and attachment to, the human erythrocyte. Distinguishing these roles could uncover unknown 
vulnerabilities of the P. falciparum receptor-ligand interactions that can be exploited to combat 
malaria. As of now, prevention and anti-malarial treatments are the main defenses against this 
disease. Perhaps, more effective, long- lasting treatments can be derived from the properties 
learned about the receptor-ligand interactions of Plasmodium falciparum during invasion. 
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Figure 1. P. falciparum Duffy Binding-Like Erythrocyte Binding Protein Structures. 
A schematic of the P. falciparum DBL-EBP proteins and the expected structure of the 
pseudogene pebl as determined by sequence analysis. The red box denotes the tandem repeated 
DBL regions F1 and F2 that comprise Region II. 
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Figure 2.Electrophoresis of JESEBL Region II PCR Product. 
Lane 1: 1kb molecular maker (New England Biolabs, Ipswich, MA), Lane 2: A band of the 
expected size of 1.89 kb for JESEBL RII.  
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Figure 3. Plasmid Vector pcDNA 3.1 myc-His B. 
A simplified schematic showing the genes for ampicillin (β-lactamase) and geneticin resistance 
(G418 R), the human cytomeglovirus and immediate-early promoter/enhancer sequences 
(CMV), the SV40 early promoter/origin of replication (SV40 ori) and polyadenylation signal 
(Poly A), the pUC origin of replication (pUC ori), the T7 promoter sequence (T7), BGH reverse 
priming sequence (BGH), and the multiple cloning site in red. The myc epitope, carboxyterminal 
hexahistidytl epitope (6X-His-tag), and termination sequence (stop) are also shown. 
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Figure 4. Electrophoresis of Purified Vector and JESEBL RII PCR Product.  
Lane 1: 1kb molecular maker (New England Biolabs, Ipswich, MA). Lane 2: Linearized plasmid 
vector of expected size 5.5kb after restriction endonuclease reactions with KpnI and BamHI and 
a phosphatase treatment of the vector. Lane 3: A band of the expected size of 1.89 kb for 
JESEBL RII. 
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Figure 5. Analysis of Positive JESEBL RII Clones.  
Plasmid DNA was purified from ten randomly selected clones grown on LB agar plates with 
ampicillin. Plasmid DNA was digested with restriction endonuclease KpnI and BamHI to liberate 
the JESEBL RII insert. Clones with inserts present were sequenced. Lane 1: 1kb molecular 
maker (New England Biolabs, Ipswich, MA). Lanes 2-11: clones 1-10, respectively. 
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TATTTGAATAGAAATAGTTTTGTTCAAAGATCATATATAAGGGGTTGTAAAGGAAAAAGAAGCACACAT
ACATGGATATGTGAAAATAAAGGGAATAATAATATATGTATTCCTGATAGACGTGTACAATTATGTATA
ACAGCTCTTCAAGATTTAAAAAATTCAGGATCTGAAACGACTGATAGAAAATTATTAAGAGATAAAGTA
TTTGATTCAGCTATGTATGAAACTGATTTGTTATGGAATAAATATGGTTTTCGTGGATTTGATGATTTT
TGTGACGATGTAAAAAATAGTTATTTAGATTATAAAGATGTTATATTTGGAACCGATTTAGATAAAAAT
AATATATCAAAGTTAGTAGAGGAATCATTAAAACGTTTTTTTAAAAAAGATAGTAGTGTACTTAATCCT
ACTGCTTGGTGGAGAAGGTATGGAACAAGACTATGGAAAACTATGATACAGCCATATGCTCATTTAGGA
TGTAGAAAACCTGATGAGAATGAACCTCAGATAAATAGATGGATTCTGGAATGGGGGAAATATAATTGT
AGATTAATGAAGGAGAAAGAAAAATTGTTAACAGGAGAATGTTCTGTTAATAGAAAAAAATCTGACTGC
TCAACCGGATGTAATAATGAGTGTTATACCTATAGGAGTCTTATTAATAGACAAAGATATGAGGTCTCT
ATATTAGGAAAAAAATATATTAAAGTAGTACGATATACTATATTTAGGAGAAAAATAGTTCAACCTGAT
AATGCTTTGGATTTTTTAAAATTAAATTGTTCTGAGTGTAAGGATATTGATTTTAAACCCTTTTTTGAA
TTTGAATATGGTAAATATGAAGAAAAATGTATGTGTCAATCATATATTGATTTAAAAATCCAATTTAAA
AATATTGATATTTGTTCATTTAATGCTCAAACAGATACTGTTTCTAGCGATAAAAGATTTTGTCTTGAA
AAGAAAGAATTTAAACCATGGCAATGTGATAAAAATTCTTTTGAAACAGTTCATCATAAAGGTGTATGT
GTGTCACCGAGAAGACAAGGTTTTTGTTTAGGAAATTTGAACTATCTACTGAATGATGATATTTATAAT
GTACATAATTCACAACTACTTATCGAAATTATAA TGGAAA
AAACATGGAACAATACTTGATAACCAGAATGCAT
TGGCTTCTAAACAAGAAGGAAAGTTATTA
GCAAATATATAAATGATAGTTATGTTGATTATAAA
GATATAGTTATTGGAAATGATTTATGGAATGATAACAACTCTATAAAAGTTCAAAATAATTTAAATTTA
ATTTTTGAAAGAAATTTTGGTTATAAAGTTGGAAGAAATAAACTCTTTAAAACAATTAAAGAATTAAAA
AATGTATGGTGGATATTAAATAGAAATAAAGTATGGGAATCAATGAGATGTGGAATTGACGAAGTAGAT
CAACGTAGAAAAACTTGTGAAAGAATAGATGAACTAGAAAACATGCCACAATTCTTTAGATGGTTTTCA
CAATGGGCACATTTCTTTTGTA TTAAATGATAAATGTACAGGT
AATAATGGAAAATCCTTATGTC
AGGAAAAAGAATATTGGGAATTAAAA
AGGATAAAACATGTCAAAATGTGTGTAC
R1
R2
R3TAATATGAATTATTGGACA
TATACTAGAAAATTAGCTTATGAAATACAATCCGTAAAATATGATAAAGATAGAAAATTATTTAGTCTT
GCTAAAGACAAAAATGTACTACATTTTTAAAGGAAAATGCAAAAAATTGTTCTAATATAGATTTTACAA
AAATATTCGATCAGCTTGACAAACTCTTTAAGGAAAGATGTTCATGTATGGATACACAAGTTTTAGAAG
TAAAAAACAAAGAAATGTTATCTATAGACTCA
F1
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Figure 6. JESEBL RII Sequencing Primers.  
Based on the expected DNA sequence for jesebl RII from P. falciparum strain Dd2/Nm 
(Accession# AY495681), six internal primers were designed for the sequencing of positive 
clones. Forward primers are indicated by the letter “F’ and highlighted in blue. Reveres primers 
are indicated by the letter “R” and are highlighted in red.  
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Figure 7. DNA Sequence Analysis of JESEBL RII Clone 10.  
Expected DNA sequence from P. falciparum strain Dd2/Nm jesebl gene (Accession# 
AY495681) in black, aligned to the positive JESEBL RII clone10, in blue. The one base pair 
substitution, resulting a silent mutation, is highlighted in red.  
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Figure 8. Protein Sequence Analysis of JESEBL RII Clone.  
Expected protein sequence from P. falciparum strain Dd2/Nm JESEBL (accession # 
AAS46312.1) aligned with the translated gene sequence from the positive JESEBL RII clone 10. 
Characteristic DBL cysteine residues are highlighted in red, myc epitope in green, and 
hexahistidyl epitope in blue.  
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Figure 9. Immunoblot Analysis of Purified Hexahistidyl Recombinant Proteins from COS-
1 Cells.  
Hexahistidyl proteins were purified from untransfected COS-1 cells and P. falciparum EBP RII 
transfected COS-1 cells by nickel-IDA column chromatography and eluates were analyzed by 
immunoblot assay, BAEBL RII and JESEBL RII were detected, EBA-175 RII was not. Arrows 
denote recombinant proteins. A: antisera for EBA-175 II. Lane 1: Chromatography elutate from 
untransfected COS-1 cells. Lane 2: Chromatography elutate from EBA-175 RII transfected COS-
1 cells. B: antisera for BAEBL RII. Lane 1: Chromatography elutate from untransfected COS-1 
cells. Lane 2: Chromatography elutate from BAEBL RII transfected COS-1 cells. C: antisera for 
JESEBL RII. Lane 1: Chromatography elutate from untransfected COS-1 cells. Lane 2: 
chromatography elutate from JESEBL RII transfected COS-1 cells.  
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Figure 10. Immunoflorescence assay of BAEBL RII stable cell line.  
After continued selection the cell line reached 100% expression as determined by IFA. The assay 
performed on the cell line with the secondary antibody alone served as a control to visualize 
nonspecific binding of the secondary antibody and the fluorescent signal produced from it.  
34 
35 
 
 
Figure 11. Immunoflorescence assay of EBA-175 RII stable cell line. 
After continued selection the cell line reached 100% expression as determined by IFA. The assay 
performed on the cell line with the secondary antibody alone served as a control to visualize 
nonspecific binding of the secondary antibody and the fluorescent signal produced from it.  
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Figure 12. Amplification of baebl RII from stably transfected CHO-K1 cell line.  
Genomic DNA was isolated from untransfected and BAEBL RII transfected CHO-K1 cells. A. 
Primers designed to amplify baebl RII were used with various templates. Lane 1: No DNA 
template, as a negative control. Lane 2: Plasmid DNA with baebl RII used to transfect the CHO-
K1 cells, as a positive control. Lane 3: BAEBL RII transfected CHO-K1 cell line DNA. Lane 4: 
Untransfected CHO-K1 DNA. B. Primers designed to amplify a 435 bp fragment of the Chinese 
hamster GAPDH gene (Holdsworth et al. 2005) were used as a positive control for the presence 
of Chinese Hamster genomic DNA. Lane 1: BAEBL RII transfected CHO-K1 cell line DNA. 
Lane 2: Untransfected CHO-K1 DNA. Lane 3: No DNA template. 
36 
 
EBA-175 RII primers
2kb
A
1 2 3 4
GAPDH primers
500bp
B
1 2 3
 
 
Figure 13. Amplification of eba-175 RII from stably transfected CHO-K1 cell line.  
Genomic DNA was isolated from untransfected and EBA-175 RII transfected CHO-K1 cells. A. 
Primers designed to amplify eba-175 RII were used with various templates. Lane 1: No DNA 
template, as a negative control. Lane 2: Plasmid DNA with eba-175 RII used to transfect the 
CHO-K1 cells, as a positive control. Lane 3: EBA-175 RII transfected CHO-K1 cell line DNA. 
Lane 4: Untransfected CHO-K1 DNA. B. Primers designed to amplify a 435 bp fragment of the 
Chinese hamster GAPDH gene (Holdsworth et al. 2005) were used as a positive control for the 
presence of Chinese Hamster genomic DNA. Lane 1: EBA-175 RII transfected CHO-K1 cell line 
DNA. Lane 2: Untransfected CHO-K1 DNA. Lane 3: No DNA template. 
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Figure 14. Expression of baebl RII from stably transfected CHO-K1 cell line cDNA.  
RNA was isolated from untransfected (panel B) and BAEBL RII transfected CHO-K1 cells 
(panel A). Reverse transcriptase (RT) PCR was performed with reverse transcriptase (+RT), to 
produce cDNA, and without reverse transcriptase as a negative control (-RT). A. Lane 1: No 
cDNA. Lane 2: PCR product produced from baebl RII primers with template of +RT cDNA. 
Lane 3: PCR product produced from baebl RII primers with template of -RT cDNA. Lane 4: 
PCR product produced from GAPDH primers with template of +RT cDNA. Lane 5: PCR 
product produced from GAPDH primers with template of –RT cDNA. B.  Lane 1: PCR product 
produced from baebl RII primers with template of +RT cDNA. Lane 2: PCR product produced 
from baebl RII primers with template of -RT cDNA. Lane 3: PCR product produced from 
GAPDH primers with template of +RT cDNA. Lane 4: PCR product produced from GAPDH 
primers with template of –RT cDNA. Lane 5: No cDNA. 
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Figure 15. Expression of eba-175 RII from stably transfected CHO-K1 cell line cDNA.  
RNA was isolated form untransfected (panel B) and EBA-175 RII transfected CHO-K1 cells 
(panel A). Reverse transcriptase (RT) PCR was performed with reverse transcriptase (+RT), to 
produce cDNA, and without reverse transcriptase as a negative control (-RT). A. Lane 1: No 
cDNA. Lane 2: PCR product produced from eba-175 RII primers with template of +RT cDNA. 
Lane 3: PCR product produced from eba-175 RII primers with template of -RT cDNA. Lane 4: 
PCR product produced from GAPDH primers with template of +RT cDNA. Lane 5: PCR 
product produced from GAPDH primers with template of –RT cDNA. B. Lane 1: PCR product 
produced from eba-175 RII primers with template of +RT cDNA. Lane 2: PCR product produced 
from eba-175 RII primers with template of -RT cDNA. Lane 3: PCR product produced from 
GAPDH primers with template of +RT cDNA. Lane 4: PCR product produced from GAPDH 
primers with template of –RT cDNA. Lane 5: No cDNA. 
39 
 
1 2
75kDa
100kDa
 
 
Figure 16. Immunoblot Analysis of Recombinant BAEBL RII from Stable CHO-K1 Cell 
Line.  
Hexahistidyl recombinant proteins were purified from untransfected CHO-K1 cells and the 
BAEBL RII transfected CHO-K1 stable cell line by nickel-IDA column chromatography and 
eluates were analyzed by immunoblot assay. Antisera for BAEBL RII detected the hexahistidyl 
recombinant BAEBL RII. Lane 1: Chromatography elutate from untransfected CHO-K1 cells. 
Lane 2: Chromatography elutate from BAEBL RII transfected CHO-K1 cells. Arrow denotes 
BAEBL RII. 
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Figure 17. Quantification of recombinant hexahistidyl P. falciparum Erythrocyte Binding 
Proteins. 
Use of the DC Protein assay from Bio-Rad (Hercules, CA) yielded a linear standard curve based 
on five concentrations of BSA and their respective average absorbencies from triplicate readings 
at 750 nm. Absorbance= 0.17353 x concentration + 0.05848, with r2 =0.99795 
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Figure 18. SYPRO Ruby Protein Stain of Whole Cell Lysates and Eluates.  
SYPRO staining of proteins after SDS-PAGE to assess the quality of the recombinant 
hexahistidyl proteins eluted from Nickel-IDA columns. Lane 1: BAEBL RII transfected CHO-
K1 cell lysate, Lane 2: BAEBL RII transfected CHO-K1 chromatography eluate. Lane 3: 
BAEBL RII transfected COS-1 cell lysate, Lane 4: BAEBL RII transfected COS-1 
chromatography eluate. Lane 5: JESEBL RII transfected COS-1 cell lysate, Lane 6: JESEBL RII 
transfected COS-1 chromatography eluate. 
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TABLES 
Table 1. Protein Quantification by Dc Protein Assay.  
Average absorbencies from triplicate readings of the three purified recombinant hexahistidyl 
proteins BAEBL RII (from COS-1 and CHO-K1 cell lines) and JESEBL RII (from the COS-1 
cells) were taken at 750 nm and the protein yields from the 1 ml of recovered eluates were 
calculated based on the standard curve linear equation; absorbance= 0.17353 x concentration + 
0.05848, with r2 =0.99795. 
Sample  Average Absorbance* Protein Yield (mg) 
BAEBL RII (CHO-K1) 0.1120 0.366 
BAEBL RII (COS-1) 0.1488 0.520 
JESEBL RII (COS-1) 0.1336 0.433 
* standard deviation of ±0.0004 
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